Prosecution Insights
Prosecution Insights
49 pending office actions • 31 art units • 46 examiners • 1 of 49 (2%) have an AI response strategy ready • 79 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 48 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 48 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 26 (53%) |
| §102 only | 3 (6%) |
| §112 only | 6 (12%) |
| Double-patenting + other | 1 (2%) |
| No statute on record | 13 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMAN, EVELYN ANNE | 2 | — | — |
| DARB, HAMZA A. | 2 | 75.0% | +31.4% |
| WANG, CHANG YU | 2 | 33.6% | +53.0% |
| SHELDEN, BION A | 1 | 21.8% | +19.3% |
| GILLIGAN, CHRISTOPHER L | 1 | 57.3% | +39.7% |
| HEIN, DEVIN C | 1 | 45.8% | +29.9% |
| KOPPOLU, VAISALI RAO | 1 | 79.8% | +24.7% |
| VARGAS, ANNA ELIZABETH | 1 | 59.4% | +53.9% |
| OKONAK, ELIZABETH LOUISE | 1 | 100.0% | +0.0% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686475 | SYSTEMS AND METHODS FOR SENSING DEFECATION EVENTS | OKONAK, ELIZABETH LOUISE | 27d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598084 | METHODS AND APPARATUSES FOR DETECTING ANOMALIES WHEN FILLING A CONTAINER WITH FLUID | KOPPOLU, VAISALI RAO | 38d overdue |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | WANG, CHANG YU | 32d overdue |
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 31d overdue |
| 18523645 | THERAPEUTIC USES OF DULAGLUTIDE | BEANE, RANDALL L | 29d overdue |
| 17433795 | MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM | DARB, HAMZA A. | 2d overdue |
| 18044618 | DEVICES AND PROCESSES FOR DELIVERY OF THERAPEUTIC FLUIDS | DARB, HAMZA A. | 14d |
| 17883072 | Anti-CGRP Antibody Formulation | WANG, CHANG YU | 14d |
| 18713758 | SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS | HEIN, DEVIN C | 33d |
| Art Unit | Apps |
|---|---|
| 3783 | 6 |
| 1658 | 4 |
| 1675 | 4 |
| 1654 | 3 |
| 1641 | 3 |
| 1621 | 2 |
| 1622 | 2 |
| 1647 | 2 |
| 3685 | 1 |
| 3683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 3685 | §103 | Non-Final OA | 31d overdue | AI Ready | Feb 19, 2025 |
| 18950247 | TECHNIQUES FOR PROCESSING WIRELESSLY BROADCAST PACKETS FROM A MEDICAL DEVICE WITH DOSE-RELATED DATA | GILLIGAN, CHRISTOPHER L | 3683 | §103 | Non-Final OA | 63d | Pending | Nov 18, 2024 |
| 18713758 | SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS | HEIN, DEVIN C | 3686 | §103 | Non-Final OA | 33d | Pending | May 28, 2024 |
| 18598084 | METHODS AND APPARATUSES FOR DETECTING ANOMALIES WHEN FILLING A CONTAINER WITH FLUID | KOPPOLU, VAISALI RAO | 2664 | §103 | Non-Final OA | 38d overdue | Pending | Mar 07, 2024 |
| 18595872 | CONNECTED INJECTION DEVICES WITH STATUS SENSING SYSTEMS | VARGAS, ANNA ELIZABETH | 3783 | §102 | Non-Final OA | 70d | Pending | Mar 05, 2024 |
| 18686475 | SYSTEMS AND METHODS FOR SENSING DEFECATION EVENTS | OKONAK, ELIZABETH LOUISE | 3792 | §103 | Non-Final OA | 27d | Pending | Feb 26, 2024 |
| 18523645 | THERAPEUTIC USES OF DULAGLUTIDE | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 29d overdue | Pending | Nov 29, 2023 |
| 18565484 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | O DELL, DAVID K | 1621 | DPOther | Non-Final OA | 61d | Pending | Nov 29, 2023 |
| 18506193 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | BURKHART, MICHAEL D | 1638 | §112 | Non-Final OA | 26d overdue | Pending | Nov 10, 2023 |
| 18288314 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | NOLAN, JASON MICHAEL | 1623 | §102 | Non-Final OA | 8d overdue | Pending | Oct 25, 2023 |
| 18489603 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18549693 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | ELENISTE, PIERRE PAUL | 1622 | §103 | Non-Final OA | 60d overdue | Pending | Sep 08, 2023 |
| 18549546 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS IN THE TREATMENT OF HALLUCINATIONS AND DEMENTIA-RELATED PSYCHOSIS | PECKHAM, RICHARD GRANT | 1627 | §112 | Non-Final OA | 15d overdue | Pending | Sep 07, 2023 |
| 18546477 | TIRZEPATIDE THERAPEUTIC METHODS | BROWN, DALIYAH MONYHE | 1654 | §103 | Non-Final OA | 39d | Pending | Aug 15, 2023 |
| 18262010 | STATUS SENSING SYSTEMS FOR CONNECTED INJECTION DEVICE | DESANTO, MATTHEW F | 3700 | §103 | Non-Final OA | 44d overdue | Pending | Jul 18, 2023 |
| 18260125 | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §103 | Non-Final OA | 3d overdue | Pending | Jun 30, 2023 |
| 18259500 | HALF-LIFE EXTENDING MOIETIES AND METHODS OF USING THE SAME | KATAKAM, SUDHAKAR | 1658 | §112 | Non-Final OA | 26d | Pending | Jun 27, 2023 |
| 18258462 | Therapeutic Peptide Formulations | KOMATSU, LI N | 1658 | Other | Non-Final OA | 56d | Pending | Jun 20, 2023 |
| 18257487 | FLUID DELIVERY SYSTEM WITH NEEDLE ASSEMBLY | THOMAN, EVELYN ANNE | 3783 | §103 | Non-Final OA | 83d | Pending | Jun 14, 2023 |
| 18323674 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | NOTTINGHAM, KYLE GREGORY | 1621 | §103 | Non-Final OA | 22d overdue | Pending | May 25, 2023 |
| 18317282 | OSCILLATING FLUIDIZED BED OLIGONUCLEOTIDE SYNTHESIZER | LAU, JONATHAN S | 1693 | §112 | Non-Final OA | 4d overdue | Pending | May 15, 2023 |
| 18143902 | VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS | SHIBUYA, MARK LANCE | 1631 | §112 | Non-Final OA | 27d | Pending | May 05, 2023 |
| 18312653 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ALDARONDO, DASIA ALI | 1647 | Other | Non-Final OA | 30d overdue | Pending | May 05, 2023 |
| 18249559 | MEDICATION DELIVERY DEVICE WITH MOISTURE SENSING SYSTEM | CARPENTER, WILLIAM R | 3783 | §103 | Final Rejection | 55d | Pending | Apr 19, 2023 |
| 18247084 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN PROTEIN PURIFICATION PROCESSES | CHHAY, BONIRATH | 1645 | §103 | Non-Final OA | 3d overdue | Pending | Mar 29, 2023 |
| 18245425 | ORAL DRUG DELIVERY DEVICE WITH EXPANDING BAND | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | 21d | Pending | Mar 15, 2023 |
| 18044618 | DEVICES AND PROCESSES FOR DELIVERY OF THERAPEUTIC FLUIDS | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 14d | Pending | Mar 09, 2023 |
| 18044504 | Therapeutic Antibody Formulations | NOAKES, SUZANNE MARIE | 1656 | §103 | Non-Final OA | 49d overdue | Pending | Mar 08, 2023 |
| 18176844 | THERAPEUTIC ANTIBODY FORMULATION | KIM, YUNSOO | 1641 | Other | Non-Final OA | 8d | Pending | Mar 01, 2023 |
| 17787015 | ENDOTOXIN DETECTION | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | 118d overdue | Pending | Feb 06, 2023 |
| 18006593 | PHYSIOLOGICAL DATA MONITORING SYSTEM | SWEARINGEN, JEFFREY R | 2445 | §103 | Non-Final OA | 7d | Pending | Jan 24, 2023 |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | MOU, LIYUAN | 1628 | Other | Final Rejection | 34d | Pending | Jan 12, 2023 |
| 18149982 | METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE | SABILA, MERCY HELLEN | 1654 | Other | Non-Final OA | 12d | Pending | Jan 04, 2023 |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | WANG, CHANG YU | 1675 | Other | Non-Final OA | 32d overdue | Pending | Dec 21, 2022 |
| 18000853 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | NIEBAUER, RONALD T | 1658 | §103 | Final Rejection | 70d | Pending | Dec 06, 2022 |
| 18054284 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES | ALLEN, MARIANNE P | 1647 | Other | Final Rejection | 139d overdue | Pending | Nov 10, 2022 |
| 17906580 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | BURKETT, DANIEL JOHN | 1624 | Other | Non-Final OA | 9d overdue | Pending | Sep 16, 2022 |
| 17905520 | MULTISPECIFIC BINDING PROTEINS AND METHODS OF DEVELOPING THE SAME | ROONEY, NORA MAUREEN | 1641 | §103 | Non-Final OA | 42d overdue | Pending | Sep 02, 2022 |
| 17883072 | Anti-CGRP Antibody Formulation | WANG, CHANG YU | 1675 | Other | Final Rejection | 14d | Pending | Aug 08, 2022 |
| 17846636 | NOVEL RNA THERAPEUTICS AND USES THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Non-Final OA | 111d overdue | Pending | Jun 22, 2022 |
| 17743864 | Treatment of Genital Psoriasis | FORD, VANESSA L | 1674 | Other | Non-Final OA | 18d overdue | Pending | May 13, 2022 |
| 17689286 | Methods of treating cancer using a combination of SERD Dosing Regimens | ADLAM, CHANTAL PETA-GAYE | 1622 | Other | Non-Final OA | 14d | Pending | Mar 08, 2022 |
| 17633631 | METHODS OF MAKING INCRETIN ANALOGS | REYNOLDS, FRED H | 1658 | §103 | Final Rejection | 28d | Pending | Feb 08, 2022 |
| 17554713 | Anti-CGRP Antibody Formulation | BORGEEST, CHRISTINA M | 1675 | §103 | Non-Final OA | 4d overdue | Pending | Dec 17, 2021 |
| 17619289 | SYSTEMS AND METHODS FOR DETECTING MISSED BOLUS DOSES | PLAYER, ROBERT AUSTIN | 1686 | Other | Final Rejection | 30d overdue | Pending | Dec 15, 2021 |
| 17439066 | INTEGRATED INSERTER/APPLICATOR FOR A DRUG DELIVERY SYSTEM PROVIDING MULTIPLE WEAR CONFIGURATIONS | THOMAN, EVELYN ANNE | 3783 | §103 | Non-Final OA | 29d | Pending | Sep 14, 2021 |
| 17462872 | ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER | SEITZ, ANTHONY JOSEPH | 1629 | Other | Final Rejection | 22d overdue | Pending | Aug 31, 2021 |
| 17433795 | MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 2d overdue | Pending | Aug 25, 2021 |
| 17211163 | COMBINATION THERAPY | BALLARD, KIMBERLY | 1675 | §102 | Non-Final OA | 10d overdue | Pending | Mar 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial